All In Biotech

Drug Trial Radar · NCT03710564

Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections

A Multicenter, Randomized, Double-masked Phase 3a Study to Assess Safety and Efficacy of Brolucizumab 6 mg q4 Weeks Compared to Aflibercept 2 mg q4 Weeks in Patients With Neovascular Age-related Macular Degeneration (nAMD) With Persistent Retinal Fluid (MERLIN)

Last checked: Nov 20, 2026Latest source record: Jan 30, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 535 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

535

Actual

Start

Oct 30, 2018

Primary completion

Dec 21, 2020

Study completion Jul 1, 2021

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Oct 18, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical study was designed to compare the safety and efficacy of brolucizumab 6 mg dosed every 4 weeks to aflibercept 2 mg dosed every 4 weeks in those neovascular age-related macular degeneration (nAMD) patients with retinal fluid despite frequent anti-Vascular Endothelial Growth Factor (VEGF) injections.

Conditions

  • Age-Related Macular Degeneration

Interventions

  • BrolucizumabBiological

    6 mg/0.05mL solution for intravitreal injection

  • AfliberceptBiological

    2 mg/0.05mL solution for intravitreal injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Best-Corrected Visual Acuity (BCVA) at Week 52Time frame: Baseline, week 52

Locations

61 sites in 2 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Phoenix, Arizona

  • Novartis Investigative Site

    Phoenix, Arizona

  • Novartis Investigative Site

    Phoenix, Arizona

  • Novartis Investigative Site

    Beverly Hills, California

  • Novartis Investigative Site

    Huntington Beach, California

  • Novartis Investigative Site

    Mountain View, California

  • Novartis Investigative Site

    Oakland, California

  • Novartis Investigative Site

    Oxnard, California

  • Novartis Investigative Site

    Palo Alto, California

  • Novartis Investigative Site

    Redlands, California

  • Novartis Investigative Site

    Sacramento, California

  • Novartis Investigative Site

    San Francisco, California

  • Novartis Investigative Site

    Santa Barbara, California

  • Novartis Investigative Site

    Colorado Springs, Colorado

  • Novartis Investigative Site

    Golden, Colorado

  • Novartis Investigative Site

    Deerfield Beach, Florida

  • Novartis Investigative Site

    Fort Lauderdale, Florida

  • Novartis Investigative Site

    Fort Myers, Florida

  • Novartis Investigative Site

    Miami, Florida

  • Novartis Investigative Site

    Mt. Dora, Florida

  • Novartis Investigative Site

    Pensacola, Florida

  • Novartis Investigative Site

    St. Petersburg, Florida

  • Novartis Investigative Site

    Stuart, Florida

  • Novartis Investigative Site

    Marietta, Georgia

  • Novartis Investigative Site

    ‘Aiea, Hawaii

  • Novartis Investigative Site

    Wheaton, Illinois

  • Novartis Investigative Site

    West Des Moines, Iowa

  • Novartis Investigative Site

    Lenexa, Kansas

  • Novartis Investigative Site

    New Orleans, Louisiana

  • Novartis Investigative Site

    West Monroe, Louisiana

  • Novartis Investigative Site

    Waldorf, Maryland

  • Novartis Investigative Site

    Boston, Massachusetts

  • Novartis Investigative Site

    Boston, Massachusetts

  • Novartis Investigative Site

    Springfield, Massachusetts

  • Novartis Investigative Site

    Royal Oak, Michigan

  • Novartis Investigative Site

    St Louis, Missouri

  • Novartis Investigative Site

    Las Vegas, Nevada

  • Novartis Investigative Site

    Reno, Nevada

  • Novartis Investigative Site

    Bloomfield, New Jersey

  • Novartis Investigative Site

    Toms River, New Jersey

Showing 40 of 61 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.